DNAPrint Genomics, Inc.: DNAPrint Genomics Scientist Delivers Presentation to Detectives at New Scotland Yard
26th Jun 2006, 18:01 GMT
SARASOTA, FL (MARKET WIRE) DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Matthew Thomas, Ph.D., the Company's Senior Scientist, delivered a lecture on forensics technology for law enforcement to detectives at the New Scotland Yard in London.
DNAPrint Genomics, Inc.: DNAPrint Genomics Scientist Delivers Presentation to Detectives at New Scotland Yard related news:
- DNAPrint Genomics Scientist Delivers Presentation to Detectives at New Scotland Yard — ArriveNet : Health
- DNAPrint Genomics, Inc.: DNAPrint Genomics Appoints Karen L. Surplus as New Chief Financial Officer — Market Wire - Management Changes
- DNAPrint names new CFO — Latest news from Tampa Bay Business Journal
- DNAPrint Genomics Appoints Karen L. Surplus As New Chief Financial Officer — RedOrbit News - Health
- Fifefighters tackle blaze at yard — BBC News | Scotland | UK Edition
- Storage yard blaze may be deliberate — Scotsman.com News - Scotland
- Muslims protest outside Scotland Yard in London, June 11. Signs ... — U.K. Photos - AFP on Yahoo! News Photos
- A scientist displays the head of half a metre (half a yard) ... — Most Emailed Photos on Yahoo! News Photos
- Police hunt for suspect after second bid to abduct children — Scotsman.com News - Scotland
- Police warning over car stranger — BBC News | Scotland | UK Edition
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech